Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
December 5, 2022

EMA validates GSK’s application for myelofibrosis therapy

The European Medicines Agency (EMA) has validated GSK’s marketing authorization application (MAA) for momelotinib to treat myelofibrosis.

GSK’s MAA for momelotinib to treat myelofibrosis is based on the data obtained from MOMENTUM trial. Credit: GSK plc.